Drug intelligence / Profile preview

Farnesyl thiopyrophosphate

Development stage: Unknown
Modality: Small Molecules

Overview

Farnesyl thiopyrophosphate (FsPP) is a synthetic analog of farnesyl pyrophosphate (FPP). It acts as an inhibitor of undecaprenyl pyrophosphate synthase (UPPs), an enzyme involved in the synthesis of undecaprenyl pyrophosphate, a lipid carrier essential for bacterial cell wall formation. FsPP has been extensively used in biochemical research to study the kinetics, inhibition, and conformational changes of UPPs, serving as a valuable tool for understanding this enzyme's function and for identifying potential drug targets.

Other names: (S)-Farnesyl thiopyrophosphate

Targets

UppS (Undecaprenyl diphosphate synthase)

Beyond the preview

Go deeper on Farnesyl thiopyrophosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Farnesyl thiopyrophosphate.

Explore the full profile